echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Movement Disorders: Diffusion imaging parameters can detect and predict Parkinson's progress

    Movement Disorders: Diffusion imaging parameters can detect and predict Parkinson's progress

    • Last Update: 2021-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Rasagiline has received attention as a potential disease improvement therapy for the treatment of Parkinson's disease (PD)
    .
    Whether rasagiline can change the disease is still questionable

    .

    David E.
    Vaillancourt
    et al.
    To determine whether rasagiline has a disease-improving effect in patients with Parkinson's disease for more than 1 year

    .
    Secondly, two diffusion magnetic resonance imaging pulse sequences were evaluated to determine the best sequence for assessing disease progression

    .
    The research results were published in the Journal of Movement Disorders

    .

    David E.
    Vaillancourt
    et al.
    To determine whether rasagiline has a disease-improving effect in patients with Parkinson's disease for more than 1 year

    .
    Secondly, two diffusion magnetic resonance imaging pulse sequences were evaluated to determine the best sequence for assessing disease progression

    .
    The research results were published in the Journal of Movement Disorders

    .

    This prospective, randomized, double-blind, placebo-controlled trial evaluated the efficacy of rasagiline at 1 mg/day for early PD within 12 months
    .
    Two kinds of diffusion magnetic resonance imaging pulse sequences were used to measure the 1-year change in the accumulation of free water in the substantia nigra (pSN), one with a repetition time (TR) of 2500 ms (short TR; n=90) and the other with a TR of 6400 ms (Long TR; n=75)

    .

    There was no significant difference in the absolute change of pSN free water accumulation among the groups (short TR: P=0.
    346; long TR: P=0.
    228)

    .
    No significant differences in secondary clinical results were found between the two groups

    .

    Long TR, not short TR, data showed that pSN free water increased significantly within one year (P=0.
    025)

    .
    The third part of the dyskinesia society unified parkinson's disease motor function rating scale increased significantly within 1 year (P=0.
    009), and the baseline free water and dyskinesia society in pSN were 1 The annual change (P=0.
    004) is related to the 1-year change in the motor retardation score (P=0.
    044)

    .

    The study did not find evidence that rasagiline at 1 mg/day for more than 1 year has an ameliorating effect on Parkinson's disease
    .
    The pSN free water increased within 1 year, and the baseline free water was correlated with the progress of clinical exercise, proving the importance of diffusion imaging parameters for detecting and predicting the progress of PD, as well as the importance of using the long TR scan to evaluate the increase of free water in the progress of PD SN
    .

    The pSN free water increased within 1 year, and the baseline free water was correlated with the progress of clinical exercise, proving the importance of diffusion imaging parameters for detecting and predicting the progress of PD, and the importance of using the long TR scan to evaluate the increase of free water in the progress of PD SN
    .
    The pSN free water increased within 1 year, and the baseline free water was correlated with the progress of clinical exercise, proving the importance of diffusion imaging parameters for detecting and predicting the progress of PD, as well as the importance of using the long TR scan to evaluate the increase of free water in the progress of PD SN
    .

    Original source

    Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline [published online ahead of print, 2021 Nov 1].
    Mov Disord.
    2021;10.
    1002/mds.
    28838.
    doi:10.
    1002/mds.
    28838

    Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline [published online ahead of print, 2021 Nov 1].
    Mov Disord.
    2021;10.
    1002/mds.
    28838.
    doi:10.
    1002/mds.
    28838
    Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline [published online ahead of print, 2021 Nov 1] Mov Disord 2021; 10.
    1002 / mds.
    28838 doi:.
    .
    .
    10.
    1002 / mds.
    28838


    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.